CN111358779A - Application of amygdalol A in preventing and treating novel coronavirus infection - Google Patents
Application of amygdalol A in preventing and treating novel coronavirus infection Download PDFInfo
- Publication number
- CN111358779A CN111358779A CN202010311165.6A CN202010311165A CN111358779A CN 111358779 A CN111358779 A CN 111358779A CN 202010311165 A CN202010311165 A CN 202010311165A CN 111358779 A CN111358779 A CN 111358779A
- Authority
- CN
- China
- Prior art keywords
- compound
- amaronol
- infection
- preventing
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- KZFYMOSMINTUQG-UHFFFAOYSA-N Amaronol A Chemical compound O=C1C=2C(O)=CC(O)=CC=2OC1(O)CC1=CC(O)=C(O)C(O)=C1 KZFYMOSMINTUQG-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000011987 methylation Effects 0.000 claims abstract description 5
- 238000007069 methylation reaction Methods 0.000 claims abstract description 5
- 239000003607 modifier Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 239000000645 desinfectant Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims description 2
- -1 hand sanitizer Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 abstract description 24
- 208000015181 infectious disease Diseases 0.000 abstract description 19
- 238000012356 Product development Methods 0.000 abstract description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof, belonging to the technical field of medicines. The effective components of the compound comprise picrine A (Amaronol A), Amaronol A derivatives (including but not limited to Amaronol A methylation products, structure modifiers and the like), and the effective use concentration range is 10 ng/ml to 1000 ug/ml or 10 ng/g to 1000 ug/g. The compound is used for product development, and the developed product is used for preventing and treating infection of new coronavirus, and can specifically weaken the infection capacity of the new coronavirus, so that the infection of the new coronavirus is prevented and treated, and the human-borne risk is reduced.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof.
Background
The novel coronavirus pneumonia, called new coronavirus pneumonia for short, is an acute infectious disease and is caused by 2019 novel coronavirus (2019-nCoV) infection. After a person is infected with the novel coronavirus, the main symptoms include respiratory symptoms, fever, cough, shortness of breath, dyspnea, etc., and in more severe cases, the infection may cause pneumonia, severe acute respiratory syndrome, renal failure, and even death. At present, aiming at diseases caused by novel coronavirus, effective antiviral drugs aiming at pathogens are lacked, and isolation treatment and symptomatic support treatment are mainly used. Meanwhile, for the vast susceptible population, the existing protective products such as masks, alcohol-containing disinfection products and the like are all in broad-spectrum protection, and no protective products which are efficient and can specifically block virus infection exist in the market. Therefore, by utilizing modern scientific technology, the development effect is clear, and the product with high efficiency and specificity for preventing and treating the new coronavirus infection meets the public requirements and has extremely important practical significance and social significance.
Disclosure of Invention
Based on the current situation that the existing protective articles can only carry out broad-spectrum protection and do not have high-efficiency and specific protective products for novel coronavirus, the invention aims to provide a compound for efficiently and specifically preventing and treating virus infection, in particular to a compound for efficiently and specifically preventing and treating novel coronavirus infection, which can weaken the infection capacity of the novel coronavirus, thereby efficiently and specifically preventing and treating the infection of the novel coronavirus and reducing the human-borne risk.
In order to realize the purpose, the invention is realized by the following technical scheme:
the compound for efficiently and specifically preventing and treating virus infection is characterized in that: the main components of the compound comprise picrine alcohol A (Amaronol A) and Amaronol A derivatives, wherein the Amaronol A derivatives comprise but are not limited to Amaronol A methylation products, structural modifiers and the like.
Further preferably, the compound is prepared by extracting from plants or chemical synthesis.
Further preferably, the compound is used in an effective concentration range of 1-1000 ug/ml or 1-1000 ug/g.
The compound is applied to preparing products with the effect of preventing and treating new coronavirus infection.
Further preferably, the product comprises a medicament, a medical device, a health product, a disinfecting product or a protecting product; the form of the medicine or health care product comprises but is not limited to tablets, granules, hard capsules, soft capsules, oral liquid, powder, mixture, pills, dripping pills, spray, aerosol, powder cloud agent, eye drops, toothpaste, mouthwash, facial masks and hand cream; the disinfectant includes but is not limited to soap, hand sanitizer, disinfectant liquid, disinfectant gel, wet tissue, laundry detergent, and mask.
The invention has the beneficial effects that:
the invention provides a compound capable of specifically targeting a novel coronavirus, wherein the effective components of the compound comprise amygdalin A (Amaronol A), Amaronol A derivatives (including but not limited to Amaronol A methylation products, structure modifiers and the like), and the effective use concentration range is 10 ng/ml to 1000 ug/ml or 10 ng/g to 1000 ug/g. The compound is used for product development, and the developed product is used for preventing and treating infection of new coronavirus, and can specifically weaken the infection capacity of the new coronavirus, so that the infection of the new coronavirus is prevented and treated, and the human-borne risk is reduced.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, preferred embodiments of the present invention will be described in detail below to facilitate understanding of the skilled person.
The invention relates to a product such as a medicine, a medical appliance, a health care product or a sterilizing product and the like containing effective components of a compound with high efficiency and specificity for preventing and treating new coronavirus infection.
Example 1
After Amaronol A in an effective concentration range is added into the disinfection gel, the residue of new coronavirus on the surface of skin can be effectively reduced, and further the infection risk is reduced.
Example 2
Amaronol A in an effective concentration range is added into the interlayer of the mask, so that new coronavirus outside the mask is effectively isolated from entering a respiratory system in a respiratory mode.
Example 3
The aerosol is added with the compound within an effective concentration range, so that the infection of new coronavirus in a respiratory system to cells of a lung is effectively eliminated, and the respiratory system infection is prevented and treated.
Example 4
The compound in the effective concentration range is added into the disinfectant and is released into the environment in a spraying mode, so that the infection capacity of the new coronavirus in the environment is reduced, and the infection risk is reduced.
Example 5
The wet tissue is added with the compound within the effective concentration range, and the hands are wiped to prevent the residue of the new coronavirus on the hands when people go out, so that the infection risk is reduced.
The invention provides a compound capable of specifically targeting a novel coronavirus, and product development is carried out by utilizing the compound. The effective components of the compound are prepared by extraction from plants or chemical synthesis, and the main components comprise picrine A (Amaronol A) and Amaronol A derivatives (including but not limited to Amaronol A methylation products, structure modifiers and the like). The effective components in the product are found in molecular interaction research, and specifically bind with the surface immunogen (ligand) of the novel coronavirus, and the binding response value of the ligand and the receptor (ACE 2) of the novel coronavirus is reduced within the effective concentration range of the compound; the research result indicates that the effective components in the product can specifically weaken the infection capacity of the new coronavirus, thereby preventing and treating the infection of the new coronavirus and reducing the human-borne risk.
Finally, it is noted that the above-mentioned preferred embodiments illustrate rather than limit the invention, and that, although the invention has been described in detail with reference to the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the invention as defined by the appended claims.
Claims (5)
1. A compound for efficiently and specifically preventing and treating virus infection is characterized in that: the main components of the compound comprise picrine alcohol A (Amaronol A) and Amaronol A derivatives, wherein the Amaronol A derivatives comprise but are not limited to Amaronol A methylation products, structural modifiers and the like.
2. The compound of claim 1, wherein: the compound is prepared by extracting from plants or chemically synthesizing.
3. The compound of claim 1, wherein: the effective using concentration range of the compound is 1-1000 ug/ml or 1-1000 ug/g.
4. Use of a compound according to any one of claims 1 to 3 for the manufacture of a product having prophylactic and therapeutic effects on a new coronavirus infection.
5. Use of a compound according to claim 4 for the preparation of a product having prophylactic and therapeutic effects on new coronavirus infection, characterized in that: the product comprises medicines, medical equipment, health products, disinfection products or protective products; the form of the medicine or health care product comprises but is not limited to tablets, granules, hard capsules, soft capsules, oral liquid, powder, mixture, pills, dripping pills, spray, aerosol, powder cloud agent, eye drops, toothpaste, mouthwash, facial masks and hand cream; the disinfectant includes but is not limited to soap, hand sanitizer, disinfectant liquid, disinfectant gel, wet tissue, laundry detergent, and mask.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010311165.6A CN111358779A (en) | 2020-04-20 | 2020-04-20 | Application of amygdalol A in preventing and treating novel coronavirus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010311165.6A CN111358779A (en) | 2020-04-20 | 2020-04-20 | Application of amygdalol A in preventing and treating novel coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111358779A true CN111358779A (en) | 2020-07-03 |
Family
ID=71199954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010311165.6A Pending CN111358779A (en) | 2020-04-20 | 2020-04-20 | Application of amygdalol A in preventing and treating novel coronavirus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111358779A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021212270A1 (en) * | 2020-04-20 | 2021-10-28 | 云南农业大学 | Application of amaronol a in prevention and treatment of novel coronavirus infection |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370634A (en) * | 2011-11-10 | 2012-03-14 | 云南农业大学 | Application of epigallocatechin gallate |
| CN105106712A (en) * | 2015-09-17 | 2015-12-02 | 王守花 | Nutritional porridge capable of helping postoperative recovery of cancer patient and preparation method thereof |
| CN105902910A (en) * | 2016-06-21 | 2016-08-31 | 刘文峰 | Respiratory tract infection treating drop for pediatric nursing and preparation method thereof |
| WO2021212270A1 (en) * | 2020-04-20 | 2021-10-28 | 云南农业大学 | Application of amaronol a in prevention and treatment of novel coronavirus infection |
-
2020
- 2020-04-20 CN CN202010311165.6A patent/CN111358779A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370634A (en) * | 2011-11-10 | 2012-03-14 | 云南农业大学 | Application of epigallocatechin gallate |
| CN105106712A (en) * | 2015-09-17 | 2015-12-02 | 王守花 | Nutritional porridge capable of helping postoperative recovery of cancer patient and preparation method thereof |
| CN105902910A (en) * | 2016-06-21 | 2016-08-31 | 刘文峰 | Respiratory tract infection treating drop for pediatric nursing and preparation method thereof |
| WO2021212270A1 (en) * | 2020-04-20 | 2021-10-28 | 云南农业大学 | Application of amaronol a in prevention and treatment of novel coronavirus infection |
Non-Patent Citations (3)
| Title |
|---|
| CHENG-WEN LIN，等: "Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds", 《ANTIVIRAL RESEARCH》 * |
| LI XC，等: "Two auronols from Pseudolarix amabilis", 《JOURNAL OF NATURAL PRODUCTS》 * |
| SHENG-PING YANG，等: "Chemical constituents from Pseudolarix Kaempferi", 《NATURAL PRODUCT RESEARCH: FORMERLY NATURAL PRODUCT LETTERS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021212270A1 (en) * | 2020-04-20 | 2021-10-28 | 云南农业大学 | Application of amaronol a in prevention and treatment of novel coronavirus infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111358781A (en) | Application of ellagic acid in preventing and treating novel coronavirus infection | |
| CN111387194A (en) | Compound for efficiently and specifically preventing and treating novel coronavirus infection and application thereof | |
| US4767788A (en) | Glutaric acid virucidal processes and compositions | |
| EA018138B1 (en) | Use of iota-carrageenan as antiviral ingredient | |
| US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| JP5470047B2 (en) | Antiviral compositions and methods of use | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| US20080057136A1 (en) | Disinfecting Composition and Methods of Making and Using Same | |
| DK169437B1 (en) | Chlorinated uracil nucleoside, this compound for use against an adenovirus infection, use of the compound for the preparation of a drug for an adenovirus infection, pharmaceutical compositions containing the compound, and process for the preparation of the compound | |
| EP0149872A2 (en) | Cosmetic composition containing glycoproteins for the skin care | |
| CN108371191A (en) | A kind of air antiseptic and its preparation method and application | |
| CN111358779A (en) | Application of amygdalol A in preventing and treating novel coronavirus infection | |
| WO2021212269A1 (en) | Application of ellagic acid in preventing and treating novel coronavirus infection | |
| WO2021212270A1 (en) | Application of amaronol a in prevention and treatment of novel coronavirus infection | |
| CN112043701A (en) | Medical application of long-chain quaternary ammonium salt compound | |
| EP4218726A1 (en) | Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method | |
| US20060287364A1 (en) | Methods of prevention of infection with HIV/AIDS, venereal disease and influenza | |
| CN112402500A (en) | Application of traditional Chinese medicine preparation in preventing and killing coronavirus | |
| JPH06505733A (en) | Use of benzimidazole anthelmintics in the treatment of microsporidiosis | |
| JP2005068089A (en) | Coronavirus disinfectant | |
| US11266145B2 (en) | Compositions comprising protocatechuic acid and methods of use | |
| RU2135160C1 (en) | Composition for nasal cavity rinsing | |
| RU2232711C1 (en) | Method of production of xenon difluoride, its rectification and application | |
| EP4104851B1 (en) | Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |
|
| RJ01 | Rejection of invention patent application after publication |